{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:00:49Z","timestamp":1768014049519,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.urolonc.2010.07.001","type":"journal-article","created":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T05:36:52Z","timestamp":1285911412000},"page":"652-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway"],"prefix":"10.1016","volume":"30","author":[{"given":"Szu-Yuan","family":"Ping","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Lun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dah-Shyong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2010.07.001_bib1","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2010.07.001_bib2","unstructured":"Health Statistics in Taiwan (2006). Part II. Statistics on Causes of Death, Department of Health, Executive Yuan, R.O.C. (Taiwan)."},{"key":"10.1016\/j.urolonc.2010.07.001_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-Year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.07.001_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01520291","article-title":"The induction of bacillus Calmette-Guerin activated killer cells requires the presence of monocytes and T-helper type-1 cells","volume":"40","author":"Thanhauser","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2010.07.001_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1464-410X.1996.01928.x","article-title":"Evaluation of local immune response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer","volume":"78","author":"Patard","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2010.07.001_bib6","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-\u03b1 2b enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2010.07.001_bib7","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1128\/iai.62.6.2315-2321.1994","article-title":"Uroepithelial cells are part of a mucosal cytokine network","volume":"62","author":"Hedges","year":"1994","journal-title":"Infect Immunol"},{"key":"10.1016\/j.urolonc.2010.07.001_bib8","first-page":"1258","article-title":"Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various anti-angiogenic effects including endothelial cell apoptosis","volume":"8","author":"Izawa","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2010.07.001_bib9","doi-asserted-by":"crossref","first-page":"23534","DOI":"10.1074\/jbc.M200172200","article-title":"Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells","volume":"277","author":"Fauconnet","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2010.07.001_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0302-2838(01)00007-0","article-title":"Molecular aspects of bladder cancer III","volume":"41","author":"Kausch","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2010.07.001_bib11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomized controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2010.07.001_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib vs. interferon-\u03b1 in metastatic renal cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2010.07.001_bib13","first-page":"1","article-title":"New paradigms for the treatment of cancer: The role of anti-angiogenesis agents","volume":"LXXIX","author":"Cherrington","year":"2000"},{"key":"10.1016\/j.urolonc.2010.07.001_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s001099900019","article-title":"Molecular and biological properties of vascular endothelial growth factor","volume":"77","author":"Ferrara","year":"1999","journal-title":"J Mol Med"},{"key":"10.1016\/j.urolonc.2010.07.001_bib15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1096\/fj.01-0700com","article-title":"SU6668 inhibits Flk-1\/KDR and PDGRFb in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice","volume":"16","author":"Laird","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.urolonc.2010.07.001_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0022-5193(76)90169-7","article-title":"Derivation and properties of Michaelis-Menton type and Hill type equations for reference ligands","volume":"59","author":"Chou","year":"1976","journal-title":"J Theor Biol"},{"key":"10.1016\/j.urolonc.2010.07.001_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jcb.10737","article-title":"Modulation of phosphatidylinositol-3-kinase\/protein kinase B and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells","volume":"91","author":"Siddiqui","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.urolonc.2010.07.001_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000137644","article-title":"Expression of vascular endothelial growth factor, receptor KDR, and p53 protein in transitional cell carcinoma of the bladder","volume":"81","author":"Liu","year":"2008","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2010.07.001_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11912-009-0034-2","article-title":"Targeting angiogenesis in bladder cancer","volume":"11","author":"Elfiky","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.urolonc.2010.07.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000102904","article-title":"Molecular therapy in urologic oncology","volume":"79","author":"Froehner","year":"2007","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2010.07.001_bib21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.mehy.2007.01.065","article-title":"Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects","volume":"69","author":"Silay","year":"2007","journal-title":"Hypotheses"},{"key":"10.1016\/j.urolonc.2010.07.001_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.urolonc.2008.03.017","article-title":"Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model","volume":"27","author":"Sonpavde","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2010.07.001_bib23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3816\/CGC.2007.n.037","article-title":"Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design","volume":"5","author":"Bradley","year":"2007","journal-title":"Clin Genitourin Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910001754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910001754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:58:13Z","timestamp":1761040693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143910001754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1078143910001754"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.07.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}